Modulation Of Regulation Research Articles

Extent of foetal exposure to maternal elexacaftor/tezacaftor/ivacaftor during pregnancy.

Cystic fibrosis (CF) patients are living longer and healthier due to improved treatments, e.g. cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy elexacaftor/tezacaftor/ivacaftor (ETI), with treatment possibly occurring in pregnancy. The risk of ETI to foetuses remain unknown. Thus the effect of maternally administered ETI on foetal genetic and structural development was investigated. Pregnant Sprague Dawley rats were orally treated with ETI (6.7mg·kg-1·day-1 elexacaftor + 3.5mg·kg-1·day-1 tezacaftor + 25 mg·kg-1·day-1 ivacaftor) for 7days from E12 to E19. Tissue samples collected at E19 were analysed using histology and RNA sequencing. Histological changes and differentially expressed genes (DEG) were assessed. No overt structural abnormalities were found in foetal pancreas, liver, lung and small intestine after 7-day ETI exposure. Very few non-functionally associated DEG in foetal liver, lung and small intestine were identified using RNA-seq. 29 DEG were identified in thymus (27 up-regulated and two down-regulated) and most were functionally linked to each other. Gene ontology enrichment analysis revealed that multiple muscle-related terms were significantly enriched. Many more DEG were identified in cortex (44 up-regulated and four down-regulated) and a group of these were involved in central nervous system and brain development. Sub-chronic ETI treatment in late pregnancy does not appear to pose a significant risk to the genetic and structural development of many foetal tissues. However, significant gene changes in foetal thymic myoid cells and cortical neuronal development requires future follow-up studies to assess the risk to these organs.

Comparison of clinical features of cystic fibrosis patients eligible but not on CFTR modulators to ineligible for CFTR modulators.

Cystic fibrosis transmembrane conductance regulator (CFTR) modulator drugs target the underlying defect and improve CFTR function. They are a part of standard care in many countries, but not all patients are eligible for these drugs due to age and genotype. Here, we aimed to determine the characteristics of non-eligible patients for CFTR modulators in the CF registry of Turkey (CFRT) to highlight their clinical needs. This retrospective cohort study included CF patient data from the CFRT in 2021. The decision of eligibility for the CFTR modulator was determined according to the 'Vertex treatment-Finder' on the Vertex® website. Demographic and clinical characteristics of patients were compared between eligible (group 1) and ineligible (group 2) groups for CFTR modulators. Among the study population (N = 1527), 873 (57.2%) were in group 1 and 654 (42.8%) were in group 2. There was no statistical difference between groups regarding sex, meconium ileus history, diagnoses via newborn screening, FEV1 z-score, CF-associated complications, organ transplant history, and death. Patients in group 2 had a higher incidence of pancreatic insufficiency (87.7% vs. 83.2%, p = .010), lower median height z-scores (-0.87 vs. -0.55, p < .001), lower median body mass index z-scores (-0.65 vs. -0.50, p < .001), longer days receiving antibiotics due to pulmonary exacerbation (0 [interquartile range, IQR: 0-2] vs. 0 [IQR: 0-7], p = 0.001), and more non-invasive ventilation support (2.6% vs. 0.9%, p = 0.008) than patients in group 1. The ineligible group had worse clinical outcomes than the eligible group. This highlights their need for life-changing drugs to improve clinical outcomes.

The criteria for chronic rhinosinusitis in children with cystic fibrosis are rarely fulfilled after initiation of CFTR modulator treatment.

The vast majority of people with cystic fibrosis (pwCF) have untreated secondary chronic rhinosinusitis (CRS). Whereas the introduction of the cystic fibrosis transmembrane conductance regulator modulator (CFTRm) treatment regime has improved the lung function of pwCF, few studies have been published examining the effect on sinonasal symptoms in children. Our aim was to explore the effect of double CFTRm treatment on CRS and olfaction in children with CF. pwCF were included in this non-randomized cross-sectional study, where an otolaryngologist performed a complete ENT examination before initiating treatment with elaxacaftor/tezacaftor/ivacaftor (ETI). Twenty-three pwCF aged 6-12 years were included. Eighteen of 23 patients were on a double CFTRm treatment, and 5 patients were CFTRm naive, respectively. Altogether, 19 had normal olfaction, 20 had none or mild CRS symptoms according to SNOT-22, and 14 had a normal endoscopy. None of the patients had symptoms of chronic rhinosinusitis lasting for more than 12 weeks, thus none of the patients fulfilled the criteria for CRS. Children with CF treated with double CFTRm have few to no symptoms of CRS and normal olfaction, which is an improvement compared with children following treatment modalities prior to CFTRm.

MarR family proteins sense sulfane sulfur in bacteria.

Members of the multiple antibiotic resistance regulator (MarR) protein family are ubiquitous in bacteria and play critical roles in regulating cellular metabolism and antibiotic resistance. MarR family proteins function as repressors, and their interactions with modulators induce the expression of controlled genes. The previously characterized modulators are insufficient to explain the activities of certain MarR family proteins. However, recently, several MarR family proteins have been reported to sense sulfane sulfur, including zero-valent sulfur, persulfide (R-SSH), and polysulfide (R-SnH, n ≥ 2). Sulfane sulfur is a common cellular component in bacteria whose levels vary during bacterial growth. The changing levels of sulfane sulfur affect the expression of many MarR-controlled genes. Sulfane sulfur reacts with the cysteine thiols of MarR family proteins, causing the formation of protein thiol persulfide, disulfide bonds, and other modifications. Several MarR family proteins that respond to reactive oxygen species (ROS) also sense sulfane sulfur, as both sulfane sulfur and ROS induce the formation of disulfide bonds. This review focused on MarR family proteins that sense sulfane sulfur. However, the sensing mechanisms reviewed here may also apply to other proteins that detect sulfane sulfur, which is emerging as a modulator of gene regulation.

Ribosome decision graphs for the representation of eukaryotic RNA translation complexity.

The application of ribosome profiling has revealed an unexpected abundance of translation in addition to that responsible for the synthesis of previously annotated protein-coding regions. Multiple short sequences have been found to be translated within single RNA molecules, within both annotated protein-coding and noncoding regions. The biological significance of this translation is a matter of intensive investigation. However, current schematic or annotation-based representations of mRNA translation generally do not account for the apparent multitude of translated regions within the same molecules. They also do not take into account the stochasticity of the process that allows alternative translations of the same RNA molecules by different ribosomes. There is a need for formal representations of mRNA complexity that would enable the analysis of quantitative information on translation and more accurate models for predicting the phenotypic effects of genetic variants affecting translation. To address this, we developed a conceptually novel abstraction that we term ribosome decision graphs (RDGs). RDGs represent translation as multiple ribosome paths through untranslated and translated mRNA segments. We termed the latter "translons." Nondeterministic events, such as initiation, reinitiation, selenocysteine insertion, or ribosomal frameshifting, are then represented as branching points. This representation allows for an adequate representation of eukaryotic translation complexity and focuses on locations critical for translation regulation. We show how RDGs can be used for depicting translated regions and for analyzing genetic variation and quantitative genome-wide data on translation for characterization of regulatory modulators of translation.

Proteomics Approach to Identify Anthracycline-induced Cardiotoxicity Mechanisms in Human Cardiac Fibroblasts

Doxorubicin-induced cardiotoxicity (DIC) is a major life-threatening side-effect of chemotherapy in cancer patients. DIC leading to heart failure is caused by numerous mechanisms, including impaired mitochondrial function, disruption of calcium homeostasis, and altered gene and protein response that triggers cell death and, eventually, fibrosis. We performed a preliminary investigation of the effect of doxorubicin (DOX) on the cardiac fibroblast proteome using mass-spectrometry. Quantitative analysis showed significantly altered expression of 186 proteins. Nine out of forty-two Dox-upregulated proteins and seventeen out of twenty-four Dox-downregulated proteins showed a reciprocal trend in expression upon inhibiting a structural scaffold protein involved in cardiac calcium channel regulation. Overall, our data suggests the involvement of pathways in regulating mitochondrial energy metabolism, matrix remodeling, cell cycle/arrest, and cell survival via Rho/Rac nuclear exchanger proteins. DIC is multifactorial, and based on our pilot data, modulation of calcium channel regulators may be a promising strategy to mitigate the progression of DIC to heart failure. Research support received from the American Heart Association, NIH and the University of Arkansas for Medical Sciences. This is the full abstract presented at the American Physiology Summit 2024 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

Impact of lumacaftor/ivacaftor on nutrition and growth in modulator-naïve children over 24 weeks

BackgroundCystic fibrosis transmembrane conductance regulator (CFTR) modulators improve nutritional status and are of importance in achieving normal growth among younger children with CF. The study was designed to examine CFTR modulator-associated changes in nutrition status, including bile acids and fatty acids after lumacaftor/ivacaftor therapy for 24 weeks. MethodsChildren 2 to 5.9 years were recruited from US and Canadian CF Centers. Eligible children were lumacaftor/ivacaftor naïve and approved to initiate therapy. Anthropometrics, diet, energy expenditure, nutrition biomarkers, pancreatic status, serum and fecal calprotectin, serum bile acids and plasma fatty acids were measured. Changes from baseline at 12 and 24 weeks were examined using mixed effects linear regression modeling. ResultsWeight-for-age z-score (WAZ) increased at 12 (0.15 ± 0.1, p = 0.01) and 24 weeks (0.23 ± 0.1, p = 0.001) from baseline following modulator therapy. Head circumference-for-age (HCZ) increased at 12 weeks compared to baseline (0.22 ± 0.1, p = 0.03) and subscapular Z score increased from baseline at 24 weeks following therapy (0.33 ± 0.1, p = 0.02). There were no changes in energy expenditure. Serum total bile acids (6.7 ± 2.0, p = 0.001), chenodeoxycholic acid (CDCA) (2.4 ± 1.1, p = 0.001), and cholic acid (CA) (3.5 ± 0.8, p < 0.0001) increased at 24 weeks compared to baseline. Fecal calprotectin decreased at 12 and 24 weeks compared to baseline (-463 ± 310, p = 0.03 and 566 ± 347, p = 0.047). A number of plasma fatty acids changed over the course of 24 weeks of therapy. Noteably, alpha-linolenic acid (ALA) decreased at 12 and 24 weeks (-24 ± 10,p = 0.03 and -18 ± 10, p = 0.02, respectively). ConclusionsOverall, young children experienced favorable changes in nutritional and growth, with the exception of plasma ALA status in the first 24 weeks of lumacaftor/ivacaftor therapy.

Considerations for the use of inhaled antibiotics for Pseudomonas aeruginosa in people with cystic fibrosis receiving CFTR modulator therapy

The major cause of mortality in people with cystic fibrosis (pwCF) is progressive lung disease characterised by acute and chronic infections, the accumulation of mucus, airway inflammation, structural damage and...

THE EFFECT OF N-STEAROYLETHANOLAMINE ON THE STRESS HORMONES LEVELS IN OLD RATS WITH INDUCED CHRONIC INFLAMMATION

Numerous studies aimed at elucidating the evolutionary acquisition of the endocannabinoid system gradually expand our understanding of the development and functioning of living organisms. It is now well-known the indispensable role of endocannabinoids in higher nervous activity and other signaling high-activity compounds. Among the representatives of this system are saturated long-chain N-acyl ethanolamines, including N-stearoylethanolamine. Previous studies have illuminated a range of important functional features of NSE on various biochemical processes, including anti-inflammatory, neuroprotective, and antidyslipidemic properties. Aim. Considering the involvement of the endocannabinoid system in neurotransmission processes and the influence of NAE on steroidogenesis, hypotheses have been formed and, accordingly, the goal of determining the involvement of NSE as an adaptogen of the sympathoadrenal and hypothalamo-pituitary-adrenal systems, including its influence on their functional state in rats during aging under conditions of low-grade chronic inflammatory processes. Methods. To achieve this goal, an experimental group of animals with "pathological" aging was formed, to which NSE was administered for some time. At the end of the experiment, blood plasma was collected from the animals, and the concentration of circulating adrenaline, corticosterone, and adrenocorticotropic hormones was analyzed using immunoassay and spectrophotometric methods. Results. During the analysis of the obtained results, geroprotective properties of NSE were identified, which likely result from an indirect pathway of its influence on humoral regulation systems. Conclusions. Analysis of the obtained results suggests that saturated N-acylethanolamines (NAEs), including NSE, may act as direct modulators of endocannabinoid system activity or indirect regulators by regulating steroidogenesis, integrating into the system of humoral regulation.

Performance enhancement of nanofluid-based photovoltaic/thermal system with a novel finned multi-block container of phase change material in the summer season of northern India

This study describes the outdoor experiments conducted on a photovoltaic/thermal (PV/T) system during the summer months of May and June in the year 2023, in northern India. The main goal of this paper is to reduce the temperature of a photovoltaic (PV) module for effective thermal regulation by implementing a hybrid cooling strategy in a PV/T system. This is achieved by integrating two techniques: multi-walled carbon nanotubes (MWCNT)-water nanofluid as the working fluid for active cooling and paraffin wax as the phase change material (PCM) for passive cooling. Therefore, the present study aims to design, fabricate, and test an innovative thermal collector with a multi-block finned absorber plate positioned beneath the PV module to promote uniform heat transfer distribution and mitigate temperature stratification within each PCM block. The proposed PV/T-PCM system's performance is assessed from energetic, exergetic, economic, and environmental standpoints compared to the PV/T system and conventional PV module. The present study also examines the impact of different concentrations (0.1–0.2 %) of MWCNT and volumetric flow rates (0.5–1.5 l/min) of both water and nanofluids as heat transfer fluids. It is shown that a desirable flow rate of 1.5 l/min yields the most favorable outcomes. The PV/T-PCM (0.2 %) system has been found to exhibit the highest levels of energetic and exergetic electrical and thermal efficiencies, with reported values of 13.25 %, 65 %, 12.81 %, and 1.66 %, respectively. The economic assessment demonstrates that the proposed PV/T-PCM system, integrating water and nanofluid, results in cost savings of 17.41 % and 19.63 % compared to a traditional uncooled PV system. In the context of environmental sustainability, the highest net CO2 mitigation is estimated to be 18.01 tons for the nanofluid-based PV/T-PCM system. Thus, the results confirm that the proposed PV/T-PCM (0.2 %) system, incorporating a hybrid cooling technique, achieves optimal performance.

EXPLORING MINDMEND: AN INNOVATIVE MENTAL HEALTH SUPPORT APP FOR AUTISTIC ADOLESCENTS AND THEIR CAREGIVERS

Teenagers with mild autism spectrum disorders (ASD) and those who care for them face difficulties. Conventional mental health therapies frequently ignore culturally specific factors that are crucial to the patient's overall wellness. The paper aims to introduce and evaluate "MindMend" a smartphone software specifically designed for teenagers with mild autism spectrum disorders (ASD) and their caregivers. It focuses on examining the effectiveness of MindMend in reducing caregiver stress and alleviating autism symptoms. Additionally, it emphasises the significance of providing comprehensive support that considers the cultural and religious nuances of the target population. The software includes modules for social skills training, emotion regulation, and cognitive-behavioural therapy. Users may participate in a helpful online community, track their progress, and set goals. Early research demonstrates encouraging outcomes in reducing caregiver stress and autism symptoms. MindMend seeks to be a flexible instrument that enhances mental health while honouring subtleties related to culture and religion. The methodology integrates software development, evidence-based therapeutic approaches, and outcome evaluation. It aims to create a specialised mental health solution for teenagers with mild autism and their caregivers. The approach strongly emphasises addressing their unique challenges and providing comprehensive support. The development of MindMend involves creating an innovative smartphone application that offers specialised content. The paper assesses how well MindMend helps reduce stress for caregivers and alleviate autism symptoms in teenagers with mild ASD. The evaluation likely includes quantitative and qualitative methods to measure the digital system's impact on users' well-being.

Changes in high-frequency aperiodic 1/f slope and periodic activity reflect post-stimulus functional inhibition in the visual cortex

Abstract It has been shown that cessation of intensive sensory stimulation is associated with a transient increase in functional inhibition in the sensory cortical areas. However, the electrophysiological correlates of this post-stimulus inhibition in the human brain have not been thoroughly investigated. To investigate post-stimulus inhibition, we analyzed magnetoencephalogram (MEG) recorded at rest and after cessation of visual stimulation of varying intensity (high-contrast gratings drifting at a slow, medium, or high rate) in 25 healthy women aged 18–40 years. We analyzed condition- and intensity-related changes in MEG parameters sensitive to functional inhibition: periodic alpha-beta power, peak alpha frequency (PAF), and 1/f aperiodic slope. We also investigated the association of these parameters with sensory sensitivity and avoidance assessed by a questionnaire. To evaluate the influence of hormonal status on the studied parameters, participants were examined twice, during the follicular and luteal phases of the menstrual cycle (MC). Regardless of the MC phase, increasing drift rate of visual gratings resulted in a proportional increase of post-stimulus posterior alpha-beta power, PAF, and a negative shift of the aperiodic (1/f) slope of the power spectrum in the high-frequency range. Compared to rest, the post-stimulus periods were characterized by higher PAF, more negative 1/f slope in posterior cortical areas, and a widespread increase in beta power. While condition- and drift-rate-dependent modulations of alpha-beta power and 1/f slope were correlated, changes in PAF did not correlate with either of them. A greater intensity-dependent increase in visual alpha-beta power predicted higher subjective sensory sensitivity/avoidance, suggesting stronger regulatory top-down modulation of the visual cortex in individuals with heightened sensitivity. Our results show that several MEG parameters concordantly indicate a post-stimulus enhancement of inhibition that is proportional to the intensity of the preceding visual stimulation. While post-stimulus changes in alpha-beta power and 1/f slope may share some common mechanisms, changes in PAF reflect a distinct aspect of inhibitory regulation. Our results inform potential inhibition-based biomarkers for clinical and translational research.

Gastrointestinal Pathologies in Pediatric Patients With Cystic Fibrosis Undergoing Endoscopy: A Single-Center Retrospective Review Over 15 Years.

Introduction Previous studies have demonstrated an increased incidence of gastrointestinal (GI) pathologies, specifically celiac disease (CD) and eosinophilic esophagitis (EoE), in patients with cystic fibrosis (CF). However, there is minimal data available regarding endoscopic findings in pediatric patients with CF and GI mucosal disease. Methods A retrospective chart review was performed on patients with CF under 18 years of age who underwent esophagogastroduodenoscopy (EGD) or colonoscopy with biopsy over a 15-year period at our institution. Patient characteristics including assigned sex at birth, CF genetic mutations (if identified), and cystic fibrosis transmembrane conductance regulator (CFTR) modulator use were recorded.Data obtained at the time of biopsy included body mass index (BMI), indication for the procedure, exocrine pancreatic status, visual endoscopic findings, and histologic findings. Results A total of 72 patients with CF were included in the study. 24% (n=17) were found to have abnormal endoscopic biopsy results. EoE (13% of all patients, n=9) and CD (6% of all patients, n=4) were the most common GI diagnoses present on endoscopic biopsy. All 3 patients taking CFTR modulator medications at the time of endoscopy had normal biopsy results. Of the 17 patients found to have abnormal pathology results, 14 (82%) were taking proton-pump inhibitor (PPI) medication at the time of endoscopy. Conclusion This study highlights the probable increased frequency of GI disease in the pediatric CF population. These findings underscore the importance of maintaining a broad differential diagnosis while considering utilization of endoscopy with biopsy in pediatric patients with CF who have GI symptoms.

Assessment of Physical Condition in Cystic Fibrosis Patients during 12-month Treatment with Cystic Fibrosis Transmembrane Conductance Regulator Modulators

Objective − To investigate the effect of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy on physical condition in children with cystic fibrosis (CF) during a 12month period.Materials and Methods − This is a retrospective cohort study including children aged ≥5 years treated with Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) or Lumacaftor/ Ivacaftor (LUM/IVA). A six-minute walk test (6MWT) was performed at baseline and at the 3-month follow-ups. Changes in spirometry and sweat chlorides, and body mass index (BMI) were also observed. Collected data were analysed for changes in 6MWT results in correlation with other parameters. The 6MWT results were compared to those predicted for healthy peers. Missing values were replaced using imputation.Results − Study includes 34 patients (median age 14 years); 28 received ELX/TEZ/ IVA, and 6 LUM/IVA. The average 6MWT walking distance (6MWD) increased from 519.3±107.7 m at baseline to 620.0±99.5 m after 12 months (P&lt;0.0001). The 12 month 6MWD values matched those expected for healthy peers. The increase in BMI z-score (P=0.019) and ppFEV1 (P&lt;0.0001) visible at the 3-month followup was sustained throughout the rest of the year. Sweat chloride concentration decreased (P&lt; 0.0001); after 12 months 13/34 subjects had values below 60 mmol/L. No correlation between 6MWD and other parameters was observed.Conclusion − Significant improvement in 6MWT results was already visible at three months following the initiation of CFTR modulator treatment. After 12 months patients performed 6MWT at a level indistinguishable from that expected of healthy peers.

Elexacaftor/tezacaftor/ivacaftor influences body composition in adults with cystic fibrosis: a fully automated CT-based analysis

A poor nutritional status is associated with worse pulmonary function and survival in people with cystic fibrosis (pwCF). CF transmembrane conductance regulator modulators can improve pulmonary function and body weight, but more data is needed to evaluate its effects on body composition. In this retrospective study, a pre-trained deep-learning network was used to perform a fully automated body composition analysis on chest CTs from 66 adult pwCF before and after receiving elexacaftor/tezacaftor/ivacaftor (ETI) therapy. Muscle and adipose tissues were quantified and divided by bone volume to obtain body size-adjusted ratios. After receiving ETI therapy, marked increases were observed in all adipose tissue ratios among pwCF, including the total adipose tissue ratio (+ 46.21%, p < 0.001). In contrast, only small, but statistically significant increases of the muscle ratio were measured in the overall study population (+ 1.63%, p = 0.008). Study participants who were initially categorized as underweight experienced more pronounced effects on total adipose tissue ratio (p = 0.002), while gains in muscle ratio were equally distributed across BMI categories (p = 0.832). Our findings suggest that ETI therapy primarily affects adipose tissues, not muscle tissue, in adults with CF. These effects are primarily observed among pwCF who were initially underweight. Our findings may have implications for the future nutritional management of pwCF.

SHIFTing goals in cystic fibrosis—managing extrapulmonary disease in the era of CFTR modulator therapy; Proceedings of the International Shaping Initiatives and Future Trends (SHIFT) Symposium

AbstractBackgroundCystic fibrosis (CF) is a life‐shortening multisystem genetic disease. Although progressive pulmonary disease is the predominant cause of morbidity and mortality, improvements in treatment for CF‐related lung disease, with associated increase in longevity, have increased the prevalence of extrapulmonary manifestations1.MethodsTo discuss these issues, a multidisciplinary meeting of international leaders and experts in the field was convened in November 2021 at the Shaping Initiatives and Future Trends Symposium with the goal of highlighting shifting management paradigms in CF. The main topics covered were: (1) nutrition and obesity, (2) exocrine pancreas, (3) CF‐related diabetes, (4) CF liver disease, (5) CF‐related bone disease, and (6) post‐lung transplant care. This document summarizes the proceedings, highlighting the key priorities and important research questions that were discussed.ResultsImproved life expectancy, the advent of cystic fibrosis transmembrane conductance regulator modulators, and the increasing appreciation of the heterogeneity or spectrum of disease are leading to a shift in management for patients with cystic fibrosis. Care should be individualized to ensure that increased longevity is accompanied by improved extra‐pulmonary care and reduced morbidity.

Spinocerebellar Ataxia Type 3 Pathophysiology-Implications for Translational Research and Clinical Studies.

The spinocerebellar ataxias (SCA) comprise a group of inherited neurodegenerative diseases. Machado-Joseph Disease (MJD) or spinocerebellar ataxia 3 (SCA3) is the most common autosomal dominant form, caused by the expansion of CAG repeats within the ataxin-3 (ATXN3) gene. This mutation results in the expression of an abnormal protein containing long polyglutamine (polyQ) stretches that confers a toxic gain of function and leads to misfolding and aggregation of ATXN3 in neurons. As a result of the neurodegenerative process, SCA3 patients are severely disabled and die prematurely. Several screening approaches, e.g., druggable genome-wide and drug library screenings have been performed, focussing on the reduction in stably overexpressed ATXN3(polyQ) protein and improvement in the resultant toxicity. Transgenic overexpression models of toxic ATXN3, however, missed potential modulators of endogenous ATXN3 regulation. In another approach to identify modifiers of endogenous ATXN3 expression using a CRISPR/Cas9-modified SK-N-SH wild-type cell line with a GFP-T2A-luciferase (LUC) cassette under the control of the endogenous ATXN3 promotor, four statins were identified as potential activators of expression. We here provide an overview of the high throughput screening approaches yet performed to find compounds or genomic modifiers of ATXN3(polyQ) toxicity in different SCA3 model organisms and cell lines to ameliorate and halt SCA3 progression in patients. Furthermore, the putative role of cholesterol in neurodegenerative diseases (NDDs) in general and SCA3 in particular is discussed.

Improved Nutritional Outcomes and Gastrointestinal Symptoms in Adult Cystic Fibrosis Patients Treated with Elexacaftor/Tezacaftor/Ivacaftor

Introduction: Cystic fibrosis transmembrane conductance regulator modulator therapy improves nutritional status and quality of life. Clinical trials have shown pancreatic insufficiency conversion, mostly in pediatric patients treated with ivacaftor. Studies with elexacaftor/tezacaftor/ivacaftor (ETI) in older patients have not suggested restoration of exocrine pancreas function, but quality data in adults are lacking. Our aim was to show the effect of ETI in adults with cystic fibrosis (CF) on nutritional status and digestive function. We hypothesized improvement of nutritional parameters and gastrointestinal symptoms, reduction of pancreatic enzyme replacement therapy, but uncertain improvement in exocrine pancreatic function. Methods: We prospectively enrolled adults with CF treated with ETI from August 2021 to June 2022. We measured anthropometric parameters, laboratory nutritional markers, change of fecal elastase, pancreatic enzymes replacement therapy needs, and gastrointestinal symptoms. Results: In the cohort of 29 patients (mean age 29.1 years), 82.8% suffered exocrine pancreatic insufficiency. After ETI, mean BMI increased by 1.20 kg/m2 (p < 0.001), mean body weight by 3.51 kg (p < 0.001), albumin by 2.81 g/L, and prealbumin by 0.06 (both p < 0.001). Only 1 patient, initially pancreatic insufficient (4.5%, p < 0.001), developed pancreatic sufficiency, indicated by increased fecal elastase from 45 μg/g to 442.1 μg/g. Mean change in lipase substitution decreased by 1,969 units/kg/day (p < 0.001) and stools frequency by 1.18 per day (p < 0.001). Conclusion: Our data suggest increased nutritional parameters, lower pancreatic substitution requirements, and improved defecation in adult CF patients on ETI. Improvement in exocrine pancreatic function might be mutation-specific and needs further study.

Persistence and evolution of Pseudomonas aeruginosa following initiation of highly effective modulator therapy in cystic fibrosis.

The highly effective cystic fibrosis transmembrane conductance regulator modulator therapy Elexakaftor/Tezacaftor/Ivacaftor (ETI) has changed cystic fibrosis (CF) disease for many people with cystic fibrosis. While respiratory symptoms are improved by ETI, we found that people with CF remain infected with Pseudomonas aeruginosa. How these persistent and evolving bacterial populations will impact the clinical manifestations of CF in the coming years remains to be seen, but the role and potentially changing face of infection in CF should not be discounted in the era of highly effective modulator therapy.

Astaxanthin and Cancer: A Comprehensive Review of Research

Astaxanthin, a red carotenoid pigment abundantly present in seafood and microalgae, has garnered increasing attention for its potential therapeutic implications in cancer. This article delves into the scientific intricacies surrounding astaxanthin and its direct effects on cancer cells. Astaxanthin exhibits remarkable anti-cancer properties, including the inhibition of cancer cell proliferation, induction of apoptosis, and suppression of metastatic processes. At the molecular level, astaxanthin showcases anti-proliferative effects through modulation of cell cycle regulators, disrupting the uncontrolled growth of cancer cells. Additionally, its ability to induce apoptosis, a programmed cell death mechanism, presents a promising avenue for curtailing aberrant cell survival. Furthermore, astaxanthin exhibits a notable impact on metastasis, inhibiting the migration and invasion of cancer cells through interference with key signalling pathways involved in these processes. This article also outlines the natural sources of astaxanthin, predominantly derived from microalgae and seafood, emphasizing its bioavailability and potential for integration into cancer therapeutic strategies. The scientific insights presented here aim to contribute to the growing body of knowledge surrounding astaxanthin and its application as a natural compound with significant anti-cancer potential. As research progresses, astaxanthin holds promise as a candidate for novel therapeutic interventions in the ongoing battle against cancer.